Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option

被引:8
作者
Hu, Can [1 ,2 ]
Zhu, Hao-te [1 ,2 ]
Xu, Zhi-yuan [1 ]
Yu, Jian-fa [1 ]
Du, Yi-an [3 ]
Huang, Ling [3 ]
Yu, Peng-fei [3 ]
Wang, Li-jing [4 ]
Cheng, Xiang-dong [1 ]
机构
[1] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Canc Hosp, Dept Abdominal Surg, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Canc Hosp, Dept Ultrason, Hangzhou, Zhejiang, Peoples R China
关键词
Esophagogastric junction; abdominal; thoracic; total gastrectomy; Siewert type II; III; gastric cancer; SIEWERT TYPE-II; RANDOMIZED CLINICAL-TRIAL; LYMPH-NODE DISSECTION; GASTROESOPHAGEAL JUNCTION; TOTAL GASTRECTOMY; NEOADJUVANT CHEMOTHERAPY; OPTIMAL EXTENT; CANCER; ESOPHAGUS; SURVIVAL;
D O I
10.1177/0300060518802923
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective The optimal surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction (AEG) is controversial. In this study, we evaluated the outcomes of total gastrectomy for Siewert type II/III AEG via the left thoracic surgical approach that is used at our center. Methods We identified 41 patients with advanced AEG in our retrospective database and analyzed their 3-year survival rate, upper surgical margin, postoperative complications, and index of estimated benefit from lymph node dissection. Results The 3-year overall survival rate of the whole group was 63%, but no difference was observed between Siewert type II and III AEGs. Esophageal exposure and lymphadenectomy were sufficient. Eight patients developed postoperative complications, but none of the patients developed anastomotic leakage. Dissection of lymph node station Nos. 19 and 110 may be necessary for patients with Siewert type II AEG. Multivariate analysis revealed that the cT category was the only independent risk factor. Conclusions Total gastrectomy via an approach from the abdominal cavity into the thoracic cavity may be an optimal surgical technique for advanced Siewert type II AEG.
引用
收藏
页码:398 / 410
页数:13
相关论文
共 50 条
  • [41] Laparoscopic en bloc lower mediastinal lymph node dissection via transhiatal approach for adenocarcinoma of esophagogastric junction
    Sakaguchi, Masazumi
    Hosogi, Hisahiro
    Kanaya, Seiichiro
    SURGICAL ONCOLOGY-OXFORD, 2021, 36 : 34 - 35
  • [42] Modified Operation to Treat Types II and III Adenocarcinoma of the Esophagogastric Junction
    Chen, Xiufeng
    Zhang, Bo
    Chen, Zhixin
    Hu, Jiankun
    Wang, Fang
    Yang, Hongxin
    Chen, Jiaping
    HEPATO-GASTROENTEROLOGY, 2012, 59 (114) : 422 - 425
  • [43] Prognostic significance of the number of lymph nodes examined in node-negative Siewert type II esophagogastric junction adenocarcinoma
    Wu, Xian-Ning
    Liu, Chang-Qing
    Tian, Jie-Yong
    Guo, Ming-Fa
    Xu, Mei-Qing
    INTERNATIONAL JOURNAL OF SURGERY, 2017, 41 : 6 - 11
  • [44] Comparison of thoracoabdominal versus abdominal-transhiatal surgical approaches in Siewert type II adenocarcinoma at the esophagogastric junction: Protocol for a prospective multicenter randomized controlled trial
    Yue, Chao
    Mo, Zhenchang
    Wu, Xiao
    Wang, Yannian
    Yang, Qinchuan
    Wang, Weidong
    Zhou, Haikun
    Gao, Ruiqi
    Ji, Panpan
    Dong, Danhong
    Zhang, Ying
    Ji, Gang
    Li, Xiaohua
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] Is Gastric Tube Reconstruction the Optimal Surgical Procedure for Siewert Type II Esophagogastric Junction Carcinoma?
    Fukuchi, Minoru
    Mochiki, Erito
    Suzuki, Okihide
    Ishiguro, Toru
    Sobajima, Jun
    Saito, Kana
    Naitoh, Hiroshi
    Kumagai, Youichi
    Baba, Hiroyuki
    Ishibashi, Keiichiro
    Ishida, Hideyuki
    ANTICANCER RESEARCH, 2014, 34 (02) : 915 - 919
  • [46] Whether the infracardiac bursa protect right pleura during laparoscopic radical operation of Siewert type II adenocarcinoma of esophagogastric junction?
    Lin, Zeyu
    Zeng, Haiping
    Xiong, Wenjun
    Li, Jin
    Chen, Yan
    Luo, Lijie
    Zheng, Yansheng
    Zhang, Zhuoxuan
    Wang, Wei
    BMC CANCER, 2022, 22 (01)
  • [47] Can Clinical Stage in the 8th Edition of the Union for International Cancer Control TNM Classification Stratify the Prognosis of Patients Undergoing Curative Surgery for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction?
    Watanabe, Hayato
    Hasegawa, Shinichi
    Kumazu, Yuta
    Hashimoto, Itaru
    Komori, Keisuke
    Suematsu, Hideaki
    Kano, Kazuki
    Fujikawa, Hirohito
    Aoyama, Toru
    Yamada, Takanobu
    Yukawa, Norio
    Yoshikawa, Takaki
    Rino, Yasushi
    Saito, Aya
    Ogata, Takashi
    Oshima, Takashi
    IN VIVO, 2023, 37 (04): : 1790 - 1796
  • [48] A minimally invasive abdominal and left thoracic approach as a palliative treatment for adenocarcinoma of the esophagogastric junction with severe stenosis: A case report
    Takeuchi, Yuta
    Ebihara, Yuma
    Nakanishi, Yoshitsugu
    Asano, Toshimichi
    Noji, Takehiro
    Kurashima, Yo
    Murakami, Soichi
    Nakamura, Toru
    Tsuchikawa, Takahiro
    Okamura, Keisuke
    Shichinohe, Toshiaki
    Hirano, Satoshi
    ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 2020, 13 (02) : 215 - 218
  • [49] Clinical application and observation of modified Ivor-Lewis surgery in Siewert type II adenocarcinoma of the Esophagogastric junction
    Yin, Qifan
    Wang, Wenhao
    Liu, Huining
    Yang, Guang
    Zhou, Shaohui
    Liu, Lijun
    JOURNAL OF CARDIOTHORACIC SURGERY, 2019, 14 (01)
  • [50] Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
    Stahl, Michael
    Walz, Martin K.
    Stuschke, Martin
    Lehmann, Nils
    Meyer, Hans-Joachim
    Riera-Knorrenschild, Jorge
    Langer, Peter
    Engenhart-Cabillic, Rita
    Bitzer, Michael
    Koenigsrainer, Alfred
    Budach, Wilfried
    Wilke, Hansjochen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 851 - 856